CU201

05/01/2002 - "CU201 inhibited the growth of human lung cancers in athymic nude mice by the intratumoral, s.c., and i.p. "
05/01/2002 - "Pharmacokinetic parameters associated with the i.v. administration of CU201 were evaluated in normal mice, and the effects of CU201 on the growth of human lung cancer xenografts were evaluated in athymic nude mice. "
05/01/2002 - "We conclude that CU201 should undergo further preclinical toxicology studies in its development as a novel targeted therapy for the treatment of lung cancers with neuroendocrine features. "
05/01/2002 - "CU201 induced apoptosis and complete growth inhibition in various lung cancer and other cancer cell lines. "
04/02/2002 - "Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism."

04/02/2002 - "At the concentration at which CU201 inhibited the growth of the cancer cells, it had no effect on the growth of normal lung cells in vitro. "
04/02/2002 - "CU201 and similar compounds offer hope of becoming a new form of targeted therapy for tumors with neuroendocrine properties."
03/11/2010 - "CU201 shows potent inhibition for small-cell lung cancer cells in vitro (ED(50)=0.15microM), as well as for small-cell lung cancer SHP-77 tumor growth in vivo. "
05/01/2002 - "CU201 induced apoptosis and complete growth inhibition in various lung cancer and other cancer cell lines. "

03/11/2010 - "CU201 shows potent inhibition for small-cell lung cancer cells in vitro (ED(50)=0.15microM), as well as for small-cell lung cancer SHP-77 tumor growth in vivo. "

12/15/2006 - "Treatment of HNSCC cells with the BK antagonist CU201 resulted in growth inhibition. "
12/15/2006 - "The combination of CU201 with the EGFR small-molecule inhibitor erlotinib resulted in additive inhibitory effects on HNSCC cell growth in vitro. "